Guardant Health Inc Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: November 5, 2026 results vs estimates
Guardant Health Inc Forecast
Guardant Health Inc short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 51.6% a year, a typical one-standard-deviation range is 171.85–198.77 over a week, 157.73–212.89 over a month and 89.78–280.84 over a year. (Signals as of 1 Nov 2026.)
Guardant Health Inc Price Chart
Guardant Health Inc Factors
YoY +33.1%
YoY +29.3%
YoY −53.1%
YoY −35.5%
YoY +88.6%
YoY −11.0%
YoY +2.9%
YoY +7.5%
YoY −21.4%
YoY +25.0%
YoY +149.0%
Guardant Health Inc fundamentals: income statement, balance sheet & cash flow
Guardant Health Inc reported revenue of $982.0m and net income of -$416.3m in FY2025, the year ended 31 December 2025 — revenue up 32.9% and net income up 4.6% on the prior year. Free cash flow was -$233.1m. These figures are as reported in the filings, not restated: 10 fiscal years and 40 quarters of history, back to December 2016. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 982.0 | 739.0 | 563.9 | 449.5 | 373.7 |
| Cost of revenue | 349.0 | 289.8 | 227.1 | 156.3 | 122.9 |
| Gross profit | 633.0 | 449.2 | 336.9 | 293.2 | 250.7 |
| Research & development | 364.2 | 347.8 | 367.2 | 373.8 | 263.2 |
| Selling, general & admin. | 706.1 | 545.1 | 534.4 | 463.8 | — |
| Operating income | -437.2 | -443.6 | -564.7 | -544.4 | -411.0 |
| EBITDA | -373.9 | -390.1 | -433.3 | -614.9 | -359.6 |
| Interest expense | 3.9 | 2.6 | 2.6 | 2.6 | 2.6 |
| Pre-tax income | -417.5 | -435.1 | -478.8 | -653.4 | -384.5 |
| Income tax | -1.3 | 1.3 | 0.7 | 1.1 | 0.3 |
| Net income | -416.3 | -436.4 | -479.4 | -654.6 | -405.7 |
Download Guardant Health Inc fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.GH.NASDAQ&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Guardant Health Inc
Explore MacroFinance macro & markets research and analysis.
Guardant Health Inc Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Guardant Health Inc; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Guardant Health Inc’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Guardant Health Inc (United States)
Guardant Health Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on Gamehost Inc.
Frequently asked questions
What is Guardant Health Inc?
What is the latest Guardant Health Inc price?
Is Guardant Health Inc in an uptrend?
How volatile is Guardant Health Inc?
What factors affect Guardant Health Inc?
Which trading strategies trade Guardant Health Inc?
How are Guardant Health Inc returns analysed?
Where can I download free Guardant Health Inc historical data?
Free Guardant Health Inc historical data (last 10 years)
Browse or instantly download the last 10 years of Guardant Health Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.GH.NASDAQ&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 145.83 |
| 2026-11-19 | 145.59 |
| 2026-11-18 | 145.14 |
| 2026-11-17 | 143.28 |
| 2026-11-16 | 144.03 |
| 2026-11-13 | 151.7 |
| 2026-11-12 | 154.86 |
| 2026-11-11 | 154.78 |
| 2026-11-10 | 155.35 |
| 2026-11-09 | 158.79 |
About this stock
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.